Floatz logo

FLUOROURACILUM

Brain Cancer

Dana-Farber Cancer InstituteSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Essen Biotech
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB
Eloxatin
Northwell Health
Phase 2B
Carboplatin
John L. Villano, MD, PhD
Phase 3B
Capecitabine
Northwell Health
Phase 2B

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →